Compare Recursion Pharmaceuticals Inc (RXRX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while TotalEnergies SE trades at $91.36 (market cap $200.03B). The key difference: TotalEnergies SE is far larger — about 107.5× Recursion Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TTE | |
|---|---|---|
Market Cap | $1.86B | $200.03B |
Sector | Health | Energy |
52-Week High | $6.79 | $93.60 |
52-Week Low | $2.84 | $57.39 |
Enterprise Value | $1.38B | $231.02B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TotalEnergies (TTE) trades at $90.1, up 1.7% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $98. Recent earnings show a beat in Q2 2026, and the company is advancing key LNG projects in Papua New Guinea and Angola. Cash flow improved to a positive $358 million in 2025, though revenue has declined from 2022 peaks.
The outlook is positive given analyst support and strategic investments, but risks include volatile oil prices and execution challenges. The stock offers value with a P/E of 11.28 and a 9.08% net margin, supported by a strong dividend history. Investors should weigh growth initiatives against energy market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
